Skip Navigation LinksHome > June 2009 - Volume 15 - Issue 6 > Long‐term outcome of maintenance infliximab therapy in child...
Inflammatory Bowel Diseases:
doi: 10.1002/ibd.20845
Original Article: Original Clinical Articles

Long‐term outcome of maintenance infliximab therapy in children with Crohn's disease

Hyams, Jeffrey S. MD1,*; Lerer, Trudy MS1; Griffiths, Anne MD2; Pfefferkorn, Marian MD3; Kugathasan, Subra MD4; Evans, Jonathan MD5; Otley, Anthony MD6; Carvalho, Ryan MD7; Mack, David MD8; Bousvaros, Athos MD9; Rosh, Joel MD10; Mamula, Petar MD11; Kay, Marsha MD12; Crandall, Wallace MD13; Oliva‐Hemker, Maria MD14; Keljo, David MD, PhD15; LeLeiko, Neal MD, PhD16; Markowitz, James MD17

Collapse Box

Abstract

Background:: Infliximab therapy has short‐term benefits in children with moderate‐to‐severe Crohn's disease (CD). We assessed the long‐term outcome of infliximab maintenance therapy in children with CD.

Methods:: We performed a multicenter cohort study of 729 pediatric patients with CD enrolled in the Pediatric Inflammatory Bowel Disease Collaborative Research Group Registry. Children younger than 16 years and newly diagnosed with CD were eligible for this study. Disease and medication information were collected prospectively from the treating physician at diagnosis, 30 days, and quarterly thereafter. No interventions were specified, per protocol.

Results:: In all, 202 of 729 patients received infliximab: 62%, 23%, and 15% within 1, 1–2, and >2 years of diagnosis, respectively. The mean age at infliximab initiation was 12.7 years. A total of 158 infliximab‐treated patients received maintenance therapy, 29 episodic (8 converted to maintenance), and 15 had incomplete follow‐up. Among 128 patients administered maintenance infliximab and followed for ≥1 year, concomitant medications at infliximab initiation included corticosteroids (52%) and immunomodulators (90%). By 1, 2, and 3 years, <10% of patients continuing on maintenance infliximab were receiving corticosteroids (P < 0.001). Following maintenance therapy initiation, 26%, 44%, and 33% of patients continuing on maintenance infliximab over 0–1, 1–2, and 2–3 years, respectively, had clinically inactive disease not requiring corticosteroids or surgery. The likelihood of continuing maintenance infliximab at 1, 2, and 3 years was 93%, 78%, and 67%, respectively.

Conclusions:: Infliximab maintenance therapy was a durable and effective treatment that was associated with prolonged corticosteroid withdrawal over a 3‐year period in children with CD.

© Crohn's & Colitis Foundation of America, Inc.

You currently do not have access to this article.

You may need to:

Note: If your society membership provides for full-access to this article, you may need to login on your society’s web site first.

Login

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.